TACO and TRALI: Biology, risk factors, and prevention strategies

Hematology (United States)

Volumn 2018, Issue 1, 2018, Pages 585-594

  Roubinian, Nareg ^a,b,c  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD COMPONENT; BLOOD TRANSFUSION; EXTRACELLULAR TRAP; HUMAN; INCIDENCE; LUNG EDEMA; PATHOGENESIS; PATHOPHYSIOLOGY; PULSE OXIMETRY; RESPIRATORY DISTRESS SYNDROME; RISK FACTOR; TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD; TRANSFUSION RELATED ACUTE LUNG INJURY; BLOOD; FEMALE; MALE; BLOOD TRANSFUSION REACTION; CLINICAL FEATURE; NONHUMAN;

BLOOD TRANSFUSION; FEMALE; HUMANS; MALE; PULMONARY EDEMA; TRANSFUSION-RELATED ACUTE LUNG INJURY;

EID: 85058884118     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2018.1.585     Document Type: Article

References (135)

1. Toy P, Gajic O, Bacchetti P, et al; TRALI Study Group. Transfusion-related acute lung injury: Incidence and risk factors. Blood. 2012;119(7):1757-1767.
2. Murphy EL, Kwaan N, Looney MR, et al; TRALI Study Group. Risk factors and outcomes in transfusion-associated circulatory overload. Am J Med. 2013;126(4):357.e29-357.e38.
3. Li G, Rachmale S, Kojicic M, et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion. 2011;51(2):338-343.
4. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: Prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886-891.
5. Clifford L, Jia Q, Yadav H, et al. Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. Anesthesiology. 2015;122(1):21-28.
6. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: Statement of a consensus panel. Transfusion. 2004;44(12):1774-1789.
7. Fatalities reported to FDA following blood collection and transfusion 2016.Available at https://www.fda.gov/downloads/BiologicsBloodVaccines/ SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ UCM598243.pdf. Accessed 16 November 2018.
8. Clifford L, Jia Q, Subramanian A, Yadav H, Schroeder DR, Kor DJ. Risk factors and clinical outcomes associated with perioperative transfusionassociated circulatory overload. Anesthesiology. 2017;126(3):409-418.
9. Roubinian NH, Hendrickson JE, Triulzi DJ, et al; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Contemporary risk factors and outcomes of transfusion-associated circulatory overload. Crit Care Med. 2018;46(4):577-585.
10. Bolton-Maggs PHB. Serious hazards of transfusion-conference report: Celebration of 20 years of UK haemovigilance. Transfus Med. 2017; 27(6):393-400.
11. Kleinman S, Grossman B, Kopko P. A national survey of transfusionrelated acute lung injury risk reduction policies for platelets and plasma in the United States. Transfusion. 2010;50(6):1312-1321.
12. Hendrickson JE, Roubinian NH, Chowdhury D, et al; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study (REDS-III). Incidence of transfusion reactions: A multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion. 2016;56(10):2587-2596.
13. Roubinian NH, Hendrickson JE, Triulzi DJ, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm. Vox Sang. 2017;112(1):56-63.
14. GoldmanM, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA; TRALI Consensus Panel. Proceedings of a consensus conference: Towards an understanding of TRALI. Transfus Med Rev. 2005;19(1):2-31.
15. Goldman M, Land K, Robillard P, Wiersum-Osselton J. Development of standard definitions for surveillance of complications related to blood donation. Vox Sang. 2016;110(2):185-188.
16. AuBuchon JP, Fung M, Whitaker B, Malasky J. AABB validation study of the CDC's National Healthcare Safety Network Hemovigilance Module adverse events definitions protocol. Transfusion. 2014;54(8): 2077-2083.
17. Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: How to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med. 2006; 34(suppl 5):S109-S113.
18. Clifford L, Jia Q, Subramanian A, et al. Characterizing the epidemiology of postoperative transfusion-related acute lung injury. Anesthesiology. 2015;122(1):12-20.
19. Rana R, Fernández-Pérez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: A retrospective study. Transfusion. 2006;46(9):1478-1483.
20. Roubinian NH, Looney MR, Kor DJ, et al; TRALI Study Group. Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions. Transfusion. 2015;55(8):1838-1846.
21. Looney MR, Roubinian N, Gajic O, et al; Transfusion-Related Acute Lung Injury Study Group. Prospective study on the clinical course and outcomes in transfusion-related acute lung injury. Crit Care Med. 2014;42(7):1676-1687.
22. Toy P, Bacchetti P, Grimes B, et al. Recipient clinical risk factors predominate in possible transfusion-related acute lung injury. Transfusion. 2015;55(5):947-952.
23. Legrand M, Gayat E. Novelties in biomarkers for the management of circulatory failure. Curr Opin Crit Care. 2013;19(5):410-416.
24. Maisel AS, Krishnaswamy P, Nowak RM, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
25. Semler MW, Marney AM, Rice TW, et al; NIH NHLBI ARDS Network. B-type natriuretic peptide, aldosterone, and fluid management in ARDS. Chest. 2016;150(1):102-111.
26. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 2006;354(21):2213-2224.
27. Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusionassociated circulatory overload. Transfusion. 2005;45(7):1056-1063.
28. Tobian AA, Sokoll LJ, Tisch DJ, Ness PM, Shan H. N-terminal probrain natriuretic peptide is a useful diagnostic marker for transfusionassociated circulatory overload. Transfusion. 2008;48(6):1143-1150.
29. Li G, Daniels CE, Kojicic M, et al. The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill. Transfusion. 2009;49(1):13-20.
30. Roubinian NH, Looney MR, Keating S, et al; TRALI Study Group. Differentiating pulmonary transfusion reactions using recipient and transfusion factors. Transfusion. 2017;57(7):1684-1690.
31. Clifford L, Singh A, Wilson GA, et al. Electronic health record surveillance algorithms facilitate the detection of transfusion-related pulmonary complications. Transfusion. 2013;53(6):1205-1216.
32. Lieberman L, Maskens C, Cserti-Gazdewich C, et al. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. Transfus Med Rev. 2013;27(4):206-212.
33. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA. 1994;271(16):1276-1280.
34. van Stein D, Beckers EA, Sintnicolaas K, et al. Transfusion-related acute lung injury reports in the Netherlands: An observational study. Transfusion. 2010;50(1):213-220.
35. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion. 2007;47(4):599-607.
36. Middelburg RA, Van Stein D, Zupanska B, et al. Female donors and transfusion-related acute lung injury: A case-referent study from the International TRALI Unisex Research Group. Transfusion. 2010; 50(11):2447-2454.
37. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med. 2007;35(7):1645-1648.
38. Kleinman SH, Triulzi DJ, Murphy EL, et al; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II. The Leukocyte Antibody Prevalence Study-II (LAPS-II): A retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or -negative components. Transfusion. 2011;51(10):2078-2091.
39. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: Implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825-1835.
40. Sachs UJ, Bux J. TRALI after the transfusion of cross-match-positive granulocytes. Transfusion. 2003;43(12):1683-1686.
41. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion. 2001;41(2):264-268.
42. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusionrelated acute lung injury: Epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101(2):454-462.
43. Strait RT, Hicks W, Barasa N, et al. MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice. J Exp Med. 2011; 208(12):2525-2544.
44. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: Report of a clinical look-back investigation. JAMA. 2002;287(15):1968-1971.
45. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009;108(3):759-769.
46. Finlay HE, Cassorla L, Feiner J, Toy P. Designing and testing a computer-based screening system for transfusion-related acute lung injury. Am J Clin Pathol. 2005;124(4):601-609.
47. Vlaar AP, Binnekade JM, Prins D, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: A nested casecontrol study. Crit Care Med. 2010;38(3):771-778.
48. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52(1):160-165.
49. Silliman CC, Curtis BR, Kopko PM, et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMNmediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. Blood. 2007;109(4):1752-1755.
50. Looney MR, Matthay MA. Animal models of transfusion-related acute lung injury. Crit Care Med. 2006;34(suppl 5):S132-S136.
51. Sachs UJ, Hattar K, Weissmann N, et al. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood. 2006;107(3):1217-1219.
52. PopovskyMA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573-577.
53. Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion. 2001;41(10):1244-1248.
54. Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: A lookback study of transfusionrelated acute lung injury. Transfusion. 2004;44(12):1683-1688.
55. Chapman CE, Stainsby D, Jones H, et al; Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the UnitedKingdomand the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440-452.
56. Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang. 2008;95(4):313-317.
57. Fung YL, Silliman CC. The role of neutrophils in the pathogenesis of transfusion-related acute lung injury. Transfus Med Rev. 2009;23(4): 266-283.
58. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: A review. Chest. 2004;126(1):249-258.
59. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: Requirements for adherence and chemokine release. Am J Physiol Cell Physiol. 2002; 283(6):C1592-C1603.
60. Müller MC, Tuinman PR, van der Sluijs KF, et al. Methylprednisolone fails to attenuate lung injury in a mouse model of transfusion related acute lung injury. Transfusion. 2014;54(4):996-1001.
61. Kapur R, Kim M, Rondina MT, Porcelijn L, Semple JW. Elevation of C-reactive protein levels in patients with transfusion-related acute lung injury. Oncotarget. 2016;7(47):78048-78054.
62. Kapur R, Kim M, Shanmugabhavananthan S, Liu J, Li Y, Semple JW. C-reactive protein enhances murine antibody-mediated transfusionrelated acute lung injury. Blood. 2015;126(25):2747-2751.
63. Vlaar AP, Hofstra JJ, Determann RM, et al. Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: A prospective nested case-control study. Crit Care Med. 2012;40(10):2813-2820.
64. Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122(7):2661-2671.
65. Thomas GM, Carbo C, Curtis BR, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood. 2012;119(26):6335-6343.
66. Kao GS, Wood IG, Dorfman DM, Milford EL, Benjamin RJ. Investigations into the role of anti-HLA class II antibodies in TRALI. Transfusion. 2003;43(2):185-191.
67. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest. 2006;116(6): 1615-1623.
68. Bux J, Becker F, Seeger W, Kilpatrick D, Chapman J, Waters A. Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Haematol. 1996;93(3):707-713.
69. Hechler B, Maître B, Magnenat S, et al. Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse. J Thromb Haemost. 2016;14(6):1255-1267.
70. McKenzie CG, Kim M, Singh TK, Milev Y, Freedman J, Semple JW. Peripheral blood monocyte-derived chemokine blockade prevents murine transfusion-related acute lung injury (TRALI). Blood. 2014; 123(22):3496-3503.
71. Middelburg RA, van Stein D, Briët E, van der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: A systematic review. Transfusion. 2008;48(10):2167-2176.
72. van Stein D, Beckers EA, Peters AL, et al. Underdiagnosing of antibodymediated transfusion-related acute lung injury: Evaluation of cellularbased versus bead-based techniques. Vox Sang. 2016;111(1):71-78.
73. Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion. 2010;50(12):2738-2744.
74. Watkins TR, Rubenfeld GD, Martin TR, et al. Effects of leukoreduced blood on acute lung injury after trauma: A randomized controlled trial. Crit Care Med. 2008;36(5):1493-1499.
75. Vlaar AP, Hofstra JJ, Determann RM, et al. The incidence, risk factors, and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: A prospective nested case-control study. Blood. 2011;117(16):4218-4225.
76. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest. 1998;101(7):1458-1467.
77. Tuinman PR, Gerards MC, Jongsma G, Vlaar AP, Boon L, Juffermans NP. Lack of evidence of CD40 ligand involvement in transfusionrelated acute lung injury. Clin Exp Immunol. 2011;165(2):278-284.
78. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455-2462.
79. Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: A retrospective study. Transfusion. 1997;37(7): 719-726.
80. Silliman CC, Moore EE, Kelher MR, Khan SY, Gellar L, Elzi DJ. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion. 2011;51(12):2549-2554.
81. Peters AL, van Hezel ME, Juffermans NP, Vlaar AP. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. Blood Rev. 2015;29(1):51-61.
82. Peters AL, Vervaart MA, van Bruggen R, et al. Non-polar lipids accumulate during storage of transfusion products and do not contribute to the onset of transfusion-related acute lung injury. Vox Sang. 2017;112(1): 25-32.
83. Toy P, Kleinman SH, Looney MR. Proposed revised nomenclature for transfusion-related acute lung injury. Transfusion. 2017;57(3):709-713.
84. Seong GM, Lee Y, Hong SB, Lim CM, Koh Y, Huh JW. Prognosis of acute respiratory distress syndrome in patients with hematological malignancies [published online ahead of print 1 January 2018]. J Intensive Care Med. doi:10.1177/0885066617753566.
85. Türkoǧlu M, Erdem GU, Suyani E, et al. Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013;18(3):123-130.
86. Kor DJ, Kashyap R, Weiskopf RB, et al. Fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: A randomized clinical trial. Am J Respir Crit Care Med. 2012;185(8): 842-850.
87. Weiskopf RB, Feiner J, Toy P, et al. Fresh and stored red blood cell transfusion equivalently induce subclinical pulmonary gas exchange deficit in normal humans. Anesth Analg. 2012;114(3):511-519.
88. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med. 2005;353(26):2788-2796.
89. Gropper MA, Wiener-Kronish JP, Hashimoto S. Acute cardiogenic pulmonary edema. Clin Chest Med. 1994;15(3):501-515.
90. Gupta SP, Nand N, Gupta MS. Left ventricular filling pressures after rapid blood transfusion in cases of chronic severe anemia. Angiology. 1982;33(5):343-348.
91. Nand N, Gupta MS, Sharma M. Effect of different amounts of blood transfusion given at different speeds on left ventricular filling pressure in cases of chronic severe anemia. Angiology. 1986;37(4):281-284.
92. Warner MA, Welsby IJ, Norris PJ, et al. Point-of-care washing of allogeneic red blood cells for the prevention of transfusion-related respiratory complications (WAR-PRC): A protocol for a multicenter randomised clinical trial in patients undergoing cardiac surgery. BMJ Open. 2017;7(8):e016398.
93. Donadee C, Raat NJ, Kanias T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;124(4):465-476.
94. Risbano MG, Kanias T, Triulzi D, et al. Effects of aged stored autologous red blood cells on human endothelial function. Am J Respir Crit Care Med. 2015;192(10):1223-1233.
95. Steiner ME, Ness PM, Assmann SF, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015; 372(15):1419-1429.
96. Lacroix J, Hébert PC, Fergusson DA, et al; Canadian Critical Care Trials Group. Age of transfused blood in critically ill adults. N Engl J Med. 2015;372(15):1410-1418.
97. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion. 2010; 50(8):1732-1742.
98. Ozier Y, Muller JY, Mertes PM, et al. Transfusion-related acute lung injury: Reports to the French Hemovigilance Network 2007 through 2008. Transfusion. 2011;51(10):2102-2110.
99. Jutzi M, Levy G, Taleghani BM. Swiss haemovigilance data and implementation of measures for the prevention of transfusion associated acute lung injury (TRALI). Transfus Med Hemother. 2008;35(2):98-101.
100. Lin Y, Saw CL, Hannach B, Goldman M. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion. 2012;52(3):567-574.
101. Eder AF, Dy BA, O'Neill EM. Predicted effect of selectively testing female donors for HLA antibodies to mitigate transfusion-related acute lung injury risk from apheresis platelets. Transfusion. 2016;56(6 pt 2): 1608-1615.
102. Lucas G, Win N, Calvert A, et al. Reducing the incidence of TRALI in the UK: The results of screening for donor leucocyte antibodies and the development of national guidelines. Vox Sang. 2012;103(1):10-17.
103. Shaz BH. Bye-bye TRALI: By understanding and innovation. Blood. 2014;123(22):3374-3376.
104. Eder AF, Dy BA, Perez JM, Rambaud M, Benjamin RJ. The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): Limitations of a predominantly male-donor plasma mitigation strategy. Transfusion. 2013;53(7):1442-1449.
105. Dunbar NM, Yazer MH; Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators. Safety of the use of group A plasma in trauma: The STAT study. Transfusion. 2017; 57(8):1879-1884.
106. Waters JH, Ness PM. Patient blood management: A growing challenge and opportunity. Transfusion. 2011;51(5):902-903.
107. Shander A, Bracey AW Jr, Goodnough LT, et al. Patient blood management as standard of care. Anesth Analg. 2016;123(4):1051-1053.
108. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: Red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025-2035.
109. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:CD002042.
110. Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: A meta-analysis and systematic review. Am J Med. 2014;127(2):124-131.e3.
111. DeZern AE, Williams K, Zahurak M, et al. Red blood cell transfusion triggers in acute leukemia: A randomized pilot study. Transfusion. 2016; 56(7):1750-1757.
112. Roubinian NH, Escobar GJ, Liu V, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III). Trends in red blood cell transfusion and 30-day mortality among hospitalized patients. Transfusion. 2014;54(10 pt 2):2678-2686.
113. Roubinian NH, Escobar GJ, Liu V, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III). Decreased red blood cell use and mortality in hospitalized patients. JAMA Intern Med. 2014; 174(8):1405-1407.
114. Mazzeffi MA, See JM, Williams B, et al. Five-year trends in perioperative red blood cell transfusion from index cases in five surgical specialties: 2011 to 2015. Transfusion. 2018;58(5):1271-1278.
115. Ellingson KD, Sapiano MRP, Haass KA, et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 2017;57(suppl 2):1588-1598.
116. Whitaker B, Rajbhandary S, Kleinman S, Harris A, Kamani N. Trends in United States blood collection and transfusion: Results from the 2013 AABB Blood Collection, Utilization, and Patient Blood Management Survey. Transfusion. 2016;56(9):2173-2183.
117. Shehata N, Forster A, Lawrence N, et al. Changing trends in blood transfusion: An analysis of 244, 013 hospitalizations. Transfusion. 2014; 54(10 pt 2):2631-2639.
118. Tinegate H, Chattree S, Iqbal A, Plews D, Whitehead J, Wallis JP; Northern Regional Transfusion Committee. Ten-year pattern of red blood cell use in the North of England. Transfusion. 2013;53(3):483-489.
119. Freedman J. The ONTraC Ontario program in blood conservation. Transfus Apheresis Sci. 2014;50(1):32-36.
120. Meybohm P, Herrmann E, Steinbicker AU, et al; PBM-study Collaborators. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient's outcome: A prospective, multicenter cohort study with a noninferiority design. Ann Surg. 2016;264(2):203-211.
121. Roubinian N, Murphy EL. Adjusting the focus on transfusionassociated circulatory overload. Anesthesiology. 2017;126(3):363-365.
122. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on Vitamin K antagonists presenting with major bleeding: A randomized, plasmacontrolled, phase IIIb study. Circulation. 2013;128(11):1234-1243.
123. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion. 2005;45(10): 1628-1631.
124. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang. 2003;85(2):88-95.
125. Andreu G, Boudjedir K, Muller JY, et al. Analysis of transfusion-related acute lung injury and possible transfusion-related acute lung injury reported to the french hemovigilance network from 2007 to 2013. Transfus Med Rev. 2018;32(1):16-27.
126. Kapur R, Kim M, Rebetz J, Rondina MT, Porcelijn L, Semple JW. Low levels of interleukin-10 in patients with transfusion-related acute lung injury. Ann Transl Med. 2017;5(16):339.
127. Kapur R, Kim M, Aslam R, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. Blood. 2017;129(18):2557-2569.
128. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: Meta-analysis. BMJ. 2008;336(7651): 1006-1009.
129. Semple JW, McVey MJ, Kim M, Rebetz J, Kuebler WM, Kapur R. Targeting transfusion-related acute lung injury: The journey from basic science to novel therapies. Crit Care Med. 2018;46(5):e452-e458.
130. Silliman CC, Kelher MR, Khan SY, et al. Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo. Blood. 2014;123(22):3488-3495.
131. Acker JP, Marks DC, Sheffield WP. Quality assessment of established and emerging blood components for transfusion. J Blood Transfus. 2016;2016:4860284.
132. Podlosky L, Poirier A, Nahirniak S, Clarke G, Acker JP. Viability of AS-3 and SAG-M red cells stored in plastic syringes for pediatric transfusion. Transfusion. 2008;48(7):1300-1307.
133. Spinella PC, Acker J. Storage duration and other measures of quality of red blood cells for transfusion. JAMA. 2015;314(23): 2509-2510.
134. Ning S, Heddle NM, Acker JP. Exploring donor and product factors and their impact on red cell post-transfusion outcomes. Transfus Med Rev. 2018;32(1):28-35.
135. Bennett-Guerrero E, Kirby BS, Zhu H, Herman AE, Bandarenko N, McMahon TJ. Randomized study of washing 40- to 42-day-stored red blood cells. Transfusion. 2014;54(10):2544-2552.